A Study of Dulanermin Administered in Combination With Camptosar/Erbitux Chemotherapy or FOLFIRI (With or Without Bevacizumab) in Subjects With Previously Treated Metastatic Colorectal Cancer

This study will assess the safety and pharmacokinetics of adding dulanermin to Camptosar/Erbitux or the FOLFIRI regimen (Camptosar, 5-FU, and leucovorin) plus bevacizumab (only for Cohort 6 subjects who have not received prior bevacizumab therapy).